Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity

@article{Keating2017Delta9TetrahydrocannabinolCannabid,
  title={Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity},
  author={G. Keating},
  journal={Drugs},
  year={2017},
  volume={77},
  pages={563-574}
}
  • G. Keating
  • Published 2017
  • Medicine
  • Drugs
  • Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (THC/CBD, Sativex®, nabiximols) is available in numerous countries worldwide for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity in patients who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. Twelve weeks’ therapy with THC/CBD improved MS-related spasticity… CONTINUE READING

    Tables and Topics from this paper.

    A Cross-Sectional Study of Cannabidiol Users
    • 39
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 61 REFERENCES
    Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
    • 57
    • Highly Influential
    • Open Access
    Early phytocannabinoid chemistry to endocannabinoids and beyond
    • 153
    • Open Access